UNSPSC 51152107: Belladonna/butabarbital

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class GA802. This VA Drug Class (GA802) classifies this compound as belonging to the group ANTIMUSCARINIC/ANTIPASMODIC COMBINATIONS.

UNSPSC 51152107 Belladonna/butabarbital is a Commodity code that shows a significant mismatch between its nominal pharmaceutical scope and the recent state and local solicitation activity tagged under it. The most recent opportunities posted under this code do not involve belladonna or butabarbital procurement; instead, they reflect community health and pharmacy benefit management initiatives centered on naloxone distribution and direct-to-manufacturer prescription contracting. The Seminole County, Florida procurement seeks naloxone units and drug deactivation systems on a competitive bid basis, while the Texas Health and Human Services Commission's Request for Information focuses on vendor capabilities for direct pharmacy contracting outside traditional pharmacy benefit manager relationships. Neither solicitation aligns with the code's stated pharmaceutical chemical classification, suggesting that state and local procurement offices may be applying this code inconsistently or as a default category for pharmacy-related acquisitions that do not fit other specialized codes.

The issuing bodies using this code span county health departments and state health agencies, with Seminole County and the Texas HHS Commission representing the documented recent activity. Geographically, the recent opportunities concentrate in Florida and Texas. The Seminole County IFB for naloxone and drug deactivation systems (IFB60459723LAS, due July 26, 2023) targets quarterly deliveries with a two-year initial term and one-year renewal option, requiring electronic bid submission through the county's e-Procurement Portal and E-Verify compliance. The Texas HHS Commission's RFI (HHS0017013, posted April 3, 2026) represents an exploratory market intelligence phase seeking vendor information on direct-to-manufacturer prescription fulfillment rather than a formal competitive solicitation. Given the limited recent record and the categorical misalignment, vendors tracking this code should verify scope alignment with individual solicitations before committing bid resources.